Companies › Viatris Innovation
2 active drug programs in 4 registered trials: 3 Phase 3, 1 Phase 1; Immunology, Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cenerimod Sphingosine 1-phosphate receptor Edg-1 modulator | S1PR1 | Phase 3 | Lupus Erythematosus, Systemic; Nephritis, Lupus | Dec 2026 |
| Selatogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 1 | Chronic Coronary Syndrome | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07615868 | Selatogrel | Phase 1 | Chronic Coronary Syndrome | Cardiovascular | Sep 2026 |
| NCT05672576 | Cenerimod | Phase 3 | Lupus Erythematosus, Systemic | Immunology | Dec 2026 |
| NCT05648500 | Cenerimod | Phase 3 | Lupus Erythematosus, Systemic | Immunology | Mar 2027 |
| NCT07201129 | Cenerimod | Phase 3 | Nephritis, Lupus | Immunology | Aug 2029 |
Jiangsu vcare pharmaceutical technology HK inno.N Prime Gene Therapeutics Hangzhou Highlightll Pharmaceutical HELP Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.